Related Experiment Video
Updated: Sep 14, 2025
Author Spotlight: Advancing Hepatic Fibrosis Diagnosis Using Magnetic Resonance Elastography and AI
Published on: July 21, 2023
Novel Insights into Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C Patients
Guanlan Liu1, Li Liu2, Xing Yang3
1Department of Ultrasound Medicine, The People's Hospital of Liaoning Province, The People's Hospital of China Medical University, Shenyang City, Liaoning Province, 110016, China.
Insights
Accurate noninvasive tests (NITs) are crucial for diagnosing liver fibrosis in chronic hepatitis C (CHC) patients. This review evaluates NITs to guide timely interventions and improve patient outcomes, reducing reliance on invasive liver biopsies.
Area of Science:
- Hepatology
- Diagnostic Imaging
- Biomarkers
Background:
- Chronic hepatitis C (CHC) poses a global health threat, with liver fibrosis severity impacting patient prognosis.
- Advanced fibrosis/cirrhosis in CHC increases risks of decompensation, hepatocellular carcinoma (HCC), and mortality.
- Early fibrosis detection is vital, but liver biopsy (LB) is invasive and has low patient acceptance.
Purpose of the Study:
- To review recent advancements in noninvasive diagnostic methods for liver fibrosis in CHC patients.
- To evaluate the accuracy and reliability of current noninvasive tests (NITs).
- To propose individualized testing protocols for diverse CHC patient profiles.
Main Methods:
- Review of recent literature on noninvasive tests for liver fibrosis in CHC.
- Evaluation of diagnostic accuracy and reliability of various NITs (ultrasound, elastography, serologic tests).
- Development of tailored testing strategies based on patient characteristics.
Main Results:
- Noninvasive tests show increasing accuracy and reliability for liver fibrosis assessment in CHC.
- Specific NITs demonstrate potential for replacing or reducing the need for liver biopsy.
- Individualized protocols can optimize fibrosis staging and patient management.
Conclusions:
- Noninvasive tests are becoming essential tools for diagnosing liver fibrosis in CHC.
- Accurate fibrosis assessment via NITs facilitates timely clinical intervention.
- Personalized approaches to NITs improve patient care and prognosis in CHC.
Abstract:
Chronic hepatitis C (CHC) represents a significant global public health challenge, with patient prognosis intricately linked to the severity of liver fibrosis. This issue is particularly critical for individuals with advanced fibrosis or cirrhosis, as they face an elevated risk of decompensation, hepatocellular carcinoma (HCC), and liver-related mortality. Consequently, the early detection and diagnosis of liver fibrosis are imperative. Although liver biopsy (LB) is considered the gold standard for fibrosis assessment, its widespread use is constrained by its invasive nature, complexity, and low patient acceptance. In recent years, various noninvasive tests (NITs) have been developed and increasingly adopted, including abdominal ultrasound, elastography, and serologic tests. This article reviews recent advancements in noninvasive diagnostic methods for assessing liver fibrosis in CHC patients, evaluates the accuracy and reliability of these methods, and proposes individualized testing protocols tailored to patients with diverse characteristics. The objective is to assist clinicians in timely intervention and to enhance patient prognosis.
More Related Videos
05:56Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
Published on: August 29, 2025
08:41Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
